In a phase I study on 112 patients [52 healthy volunteers with triglycerides (TG) > 80 mg/dL, 40 patients affected by hypertriglyceridemia (TG > 300 mg/dL), and 20 patients affected by chylomicronemia (TG > 880 mg/dL)], ARO-APOC3 was administered to 88 participants, while the placebo was administered to the remaining 24 participants by the subcutaneous route, either once or twice, with doses given on day 1 and day 29. The gene discussed is APOC3; the disease is hypertriglyceridemia.